Literature DB >> 3286041

Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris.

N Toyosaki1, T Toyo-oka, T Natsume, T Katsuki, T Tateishi, T Yaginuma, S Hosoda.   

Abstract

The antianginal effects of diltiazem and nifedipine alone and in combination were evaluated in a double-blind, randomized, placebo-controlled trial in 11 patients (nine men and two women, 57 +/- 8 years old) with stable effort angina. Each patient received placebo, 30 mg of diltiazem, 10 mg of nifedipine, and 30 mg of diltiazem plus 10 mg of nifedipine four times daily for 1 week each. Antianginal efficacy was assessed by means of a treadmill exercise test. The exercise tolerance time was significantly prolonged from 235.1 +/- 52 (placebo period) to 342.2 +/- 101 sec by diltiazem (p less than .01) and to 325.6 +/- 73 sec by nifedipine (p less than .01). The drug combination further prolonged exercise time to 451.1 +/- 103 sec, which was significantly longer than the interval attained with either diltiazem (p less than .01) or nifedipine (p less than .01) alone. The plasma concentration of diltiazem was unaffected by the addition of nifedipine, whereas the plasma nifedipine concentration was significantly increased from 34.8 +/- 11 to 106.4 +/- 37 ng/ml (p less than .001) by the concomitant administration of diltiazem. These data suggest that exercise tolerance in patients with effort angina is increased by the concomitant administration of diltiazem and nifedipine associated with an increase in the nifedipine plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286041     DOI: 10.1161/01.cir.77.6.1370

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.

Authors:  Tomie Kawada; Mikio Nakazawa; Sakura Nakauchi; Ken Yamazaki; Ryoichi Shimamoto; Masashi Urabe; Jumi Nakata; Chieko Hemmi; Fujiko Masui; Toshiaki Nakajima; Jun-Ichi Suzuki; John Monahan; Hiroshi Sato; Tomoh Masaki; Keiya Ozawa; Teruhiko Toyo-Oka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.

Authors:  T Tateishi; H Nakashima; T Shitou; Y Kumagai; K Ohashi; S Hosoda; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

5.  The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Authors:  H Sakai; S Kobayashi; K Hamada; S Iida; H Akita; E Tanaka; E Uchida; H Yasuhara
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 6.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

7.  Case studies in hypertension. Dihydropyridine/nondihydropyridine calcium channel blocker combination therapy.

Authors:  Joe Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-01       Impact factor: 3.738

Review 8.  Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 9.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Authors:  Shufeng Zhou; Eli Chan; Xiaotian Li; Min Huang
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.